Transcription of Public Assessment Report Decentralised Procedure
{{id}} {{{paragraph}}}
Public Assessment Report Decentralised Procedure LORAZEPAM 1MG TABLETS LORAZEPAM TABLETS Procedure No: UK/H/3130/001 & 002/DC UK/H/4683/001 & 002/DC UK/H/4684/001 & 002/DC UK/H/4685/001 & 002/DC UK Licence No: PL 20117/0161 & 0162 PL 20117/0191 & 0192 PL 20117/0193 & 0194 PL 20117/0195 & 0196 Morningside Healthcare Limited PAR Lorazepam 1 & Tablets UK/H/3130, 4683-5/001-2/DC 2 LAY SUMMARY On 23 September 2012, Germany, Estonia, Spain, Ireland, Lithuania, the Netherlands and the UK agreed to grant Marketing Authorisations to Morningside Healthcare Limited for the medicinal products Lorazepam 1 and Tablets (PL 20117/0161-2 UK/H/3130 & 4683-5/001 & 002/DC).
Public Assessment Report Decentralised Procedure LORAZEPAM 1MG TABLETS LORAZEPAM 2.5MG TABLETS Procedure No: UK/H/3130/001 & 002/DC UK/H/4683/001 & 002/DC
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
RECOMMENDATIONS ON MULTIPLE/DUPLICATE, RECOMMENDATIONS ON MULTIPLE/DUPLICATE APPLICATIONS, MUTUAL RECOGNITION AND DECENTRALISED PROCEDURES, The Mutual Recognition and Decentralised Procedures, Quick Response (QR) codes in the labelling and, Mutual recognition, And decentralised, Decentralised Procedure, Decentralised Procedure PENTHROX 3mL inhalation vapour, liquid, Procedure, All About Regulatory Affairs, Commission Regulation, ECTD Guidance Document, EU regulatory framework and the role, QRD Human Product Information Template